220 related articles for article (PubMed ID: 17591826)
1. Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib.
Bracarda S; Caserta C; Sordini L; Rossi M; Hamzay A; Crinò L
Ann Oncol; 2007 Jun; 18 Suppl 6():vi22-5. PubMed ID: 17591826
[TBL] [Abstract][Full Text] [Related]
2. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Strumberg D
Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib.
Rini BI
Expert Opin Pharmacother; 2006 Mar; 7(4):453-61. PubMed ID: 16503817
[TBL] [Abstract][Full Text] [Related]
4. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
6. Randomized discontinuation trial of sorafenib (BAY 43-9006).
Jain L; Venitz J; Figg WD
Cancer Biol Ther; 2006 Oct; 5(10):1270-2. PubMed ID: 16969070
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib for the treatment of advanced renal cell carcinoma.
Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib [corrected] in kidney cancer.
Escudier B
Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
[No Abstract] [Full Text] [Related]
9. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
Grandinetti CA; Goldspiel BR
Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
[TBL] [Abstract][Full Text] [Related]
10. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
Hiles JJ; Kolesar JM
Am J Health Syst Pharm; 2008 Jan; 65(2):123-31. PubMed ID: 18192256
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib.
Hasskarl J
Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
[TBL] [Abstract][Full Text] [Related]
12. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Leung HW; Chan AL
Clin Ther; 2011 Jun; 33(6):708-16. PubMed ID: 21704235
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
Gollob JA
Clin Genitourin Cancer; 2005 Dec; 4(3):167-74. PubMed ID: 16425993
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib: in advanced renal cancer.
McKeage K; Wagstaff AJ
Drugs; 2007; 67(3):475-83; discussion 484-5. PubMed ID: 17335301
[TBL] [Abstract][Full Text] [Related]
15. [Sorafenib(Nexavar)].
Miyanaga N; Akaza H
Gan To Kagaku Ryoho; 2009 Jun; 36(6):1029-33. PubMed ID: 19542731
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib in advanced clear-cell renal-cell carcinoma.
Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Siebels M; Negrier S; Chevreau C; Solska E; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Freeman S; Schwartz B; Shan M; Simantov R; Bukowski RM;
N Engl J Med; 2007 Jan; 356(2):125-34. PubMed ID: 17215530
[TBL] [Abstract][Full Text] [Related]
17. GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC).
Kawazoe H; Bilim VN; Ugolkov AV; Yuuki K; Naito S; Nagaoka A; Kato T; Tomita Y
Biochem Biophys Res Commun; 2012 Jul; 423(3):490-5. PubMed ID: 22683636
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib for the treatment of renal cancer.
Strumberg D
Expert Opin Pharmacother; 2012 Feb; 13(3):407-19. PubMed ID: 22263843
[TBL] [Abstract][Full Text] [Related]
19. An update on the medical therapy of advanced metastatic renal cell carcinoma.
Kruck S; Merseburger AS; Gakis G; Kramer MW; Stenzl A; Kuczyk MA
Scand J Urol Nephrol; 2008; 42(6):501-6. PubMed ID: 18615363
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]